What is U.S. Bancorp's current share repurchase authorization?

U.S. Bancorp has an existing $5 billion share repurchase program with $4.1 billion of remaining capacity as of March 31, 2026. The filing does not disclose the date the original $5 billion program was authorized or when it expires.

Does this filing announce a new buyback program?

No. This 8-K discloses capacity remaining under an existing program as part of the company's Dodd-Frank Act Stress Test commentary. No new authorization, amendment, or execution details are announced in this filing.

How does U.S. Bancorp's capital position support buybacks?

The company's CET1 ratio of 10.8 percent as of March 31, 2026 exceeds the regulatory minimum of 7.1 percent by a substantial margin, indicating significant capital available for discretionary actions including share repurchases. Buyback execution would remain subject to maintaining these regulatory ratios.

What is the stress capital buffer (SCB) and how does it affect buybacks?

The SCB is a regulatory requirement that, when added to the Basel III CET1 minimum of 4.5 percent, requires U.S. Bancorp to maintain a CET1 ratio at or above 7.1 percent. U.S. Bancorp's SCB remains at 2.6 percent through October 1, 2027, meaning any share repurchases must not reduce the CET1 ratio below this threshold.

What execution mechanism is used for repurchases under this program?

The filing does not specify the execution mechanism (Rule 10b-18 open-market purchases, accelerated share repurchase, 10b5-1 plan, or other method) for the remaining capacity under the existing program.

USB-PS 8-K Filed 2026-06-24 Execution disclosure

U.S. Bancorp reports $4.1B remaining capacity under share repurchase program

Company maintains $5B program authorization; capacity disclosed in DFAST stress test results announcement.

Remaining$4.1B

MechanismNot specified

What the filing says

U.S. Bancorp disclosed that as of March 31, 2026, it had $4.1 billion of remaining capacity under its existing $5 billion share repurchase program in its comments on the Federal Reserve's Dodd-Frank Act Stress Test (DFAST) results. The disclosure came as the company announced capital actions including a 3.8 percent increase in its quarterly common stock dividend from $0.52 to $0.54 per share, subject to board approval and effective in the third quarter of 2026.

The company's regulatory capital position remains strong, with a Common Equity Tier 1 (CET1) capital to risk-weighted assets ratio of 10.8 percent as of March 31, 2026, well above regulatory requirements. The stress capital buffer (SCB) for U.S. Bancorp will remain unchanged at 2.6 percent until October 1, 2027, requiring the company to maintain a CET1 ratio at or above 7.1 percent.

The filing does not specify a new authorization amount or execution details for the remaining repurchase capacity, only disclosing the existing program's remaining availability as part of the company's capital management disclosure under stress test results.

Additionally, as of March 31, 2026, U.S. Bancorp had $4.1 billion of remaining capacity under its existing $5 billion share repurchase program. — US BANCORP \DE\ 8-K filing · View on SEC EDGAR →

What this means

U.S. Bancorp's disclosure of $4.1 billion in remaining repurchase capacity indicates the company has deployed approximately $900 million of its original $5 billion authorization. The filing does not reveal execution details, timing, or whether the company intends to use the remaining capacity. The disclosure appears in the context of stress test results and capital management planning, suggesting buybacks are contingent on maintaining regulatory capital ratios well above the 7.1 percent CET1 floor. The filing provides transparency on available capital flexibility but does not commit the company to future repurchases.

Frequently asked questions

What is U.S. Bancorp's current share repurchase authorization?: U.S. Bancorp has an existing $5 billion share repurchase program with $4.1 billion of remaining capacity as of March 31, 2026. The filing does not disclose the date the original $5 billion program was authorized or when it expires.
Does this filing announce a new buyback program?: No. This 8-K discloses capacity remaining under an existing program as part of the company's Dodd-Frank Act Stress Test commentary. No new authorization, amendment, or execution details are announced in this filing.
What other capital actions did U.S. Bancorp announce?: The company announced a 3.8 percent increase in its quarterly common stock dividend from $0.52 to $0.54 per share, subject to board approval and effective in the third quarter of 2026.
How does U.S. Bancorp's capital position support buybacks?: The company's CET1 ratio of 10.8 percent as of March 31, 2026 exceeds the regulatory minimum of 7.1 percent by a substantial margin, indicating significant capital available for discretionary actions including share repurchases. Buyback execution would remain subject to maintaining these regulatory ratios.
What is the stress capital buffer (SCB) and how does it affect buybacks?: The SCB is a regulatory requirement that, when added to the Basel III CET1 minimum of 4.5 percent, requires U.S. Bancorp to maintain a CET1 ratio at or above 7.1 percent. U.S. Bancorp's SCB remains at 2.6 percent through October 1, 2027, meaning any share repurchases must not reduce the CET1 ratio below this threshold.
What execution mechanism is used for repurchases under this program?: The filing does not specify the execution mechanism (Rule 10b-18 open-market purchases, accelerated share repurchase, 10b5-1 plan, or other method) for the remaining capacity under the existing program.

existing-program capacity-disclosure stress-test banking-sector regulatory-capital capital-management

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.